Regeneron Pharmaceuticals, Inc.

Sloan-kettering Institute for Cancer Research

Psma Development Company, LLC

Pfizer Corporation

Amgen Fremont Inc.

Progenics Pharmaceuticals, Inc.

Dangshe Ma

William C Olson

Gavin Thurston

David A Scheinberg

Marcus Kelly

Michael R McDevitt

Richard Tavare

Gerald P Donovan

Paul J Maddon

Norbert Schuelke

Jason Gardner

George Sgouros

Jason T Giurleo

Larry L Green

Jaspal Singh Kang

Naoya Tsurushita

Lioudmila Tchistiakova

Shankar Kumar

Pavel Strop

Brian E Toki

Puja Sapra

Kimberly Ann Marquette

Edmund Graziani

Lawrence Nathan Tumey

Albert Cupo

Robert J Israel

Fang Jin

Ronald D Finn

Paul Borchardt

Yun Kang

Brian Kennedy

Kirsten Nagashima

Stephen Morris

Frank Loganzo, Jr

Andre J Marozsan

Robert Israel

Norbert Schulke

Donovan Gerald

Peter D Senter

Nadira Anarkali Prashad

Kimberley Ann Marquette

Edmund Idris Graziani

Kiran Manohar Khandke

Eric M Bennett

Svetlana O Doronina

Michael Mcdevitt

Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.

Anti-CD8 antibodies and uses thereof

Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.

Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

Site specific HER2 antibody drug conjugates

Disclosed herein are anti-IL-13-R&#x3b1;2 antibodies and antibody drug conjugates and methods for preparing and using the same.

Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates

The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.

PSMA antibodies and uses thereof

The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Alpha emitting constructs and uses thereof

Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine.

Methods for killing PSMA-expressing, taxane-resistant cancer cells

Provided herein are reagents, compositions, and therapies with which to treatinfection and related disease conditions and pathologies, such as-associated diarrhea, resulting from infection bybacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B ofand neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

[object Object]

The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (&#x3e;1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Alpha-emitting constructs and uses thereof

Growing community of inventors

Millwood, NY, United States of America

Dangshe Ma